Proton pump inhibitors (PPIs) – pantoprazole sodium
Last updated on October 6, 2022
|
Generic name |
pantoprazole sodium | |
|---|---|---|
| Strength |
40 mg |
|
| Form |
tablet |
|
|
Criteria |
Approval period |
|---|---|
|
1. For gastroesophageal reflux disease (GERD), reflux esophagitis, duodenal ulcer, or gastric ulcer |
Indefinite |
|
OR |
|
|
2. For Barrett's esophagus, Zollinger-Ellison syndrome, connective tissue disease, e.g., lupus, scleroderma, CREST |
Indefinite |
|
OR |
|
|
3. For eradication of Helicobacter pylori as part of triple therapy |
14 days |
| PLUS | |
Failure of reasonable trials of, or intolerance to, rabeprazole AND pantoprazole magnesium |
Practitioner exemptions
- No practitioner exemptions
Special notes
-
CREST is an acronym for the five main features of the limited form of scleroderma: calcinosis, Raynaud’s disease, esophageal dysmotility, sclerodactyly, and telangiectasia.
-
A reasonable trial of rabeprazole and pantoprazole magnesium is considered a trial at usual adult doses for at least 4 weeks each of rabeprazole and pantoprazole magnesium.